🚀
Enjoy a 7-Day Free Trial Thru Apr 25, 2024!
✨
Sign Up
Login
Free Sign-up
Login
7-Day Free Trial
Home
Homepage
Membership Levels
About Us
General Discussion
Complete Stock List
The book
Membership Data Coverage
Founder's Message
Free Trial
Referral Program
Partner Program
GuruFocus Podcast
Screeners
GuruFocus Screeners
All-In-One Screener
Ben Graham Lost Formula
Canadian Faster Growers
CEO Buys
CEO Buys after Price Drop > 20%
Dividend Kings 2023
Dividend Aristocrats 2023
Dividend Growth Portfolio
Dividend Income Portfolio
Fast Growers
Good Companies
Hedge Fund Guru Top 10 Aggregated
High Quality
High Quality Low Capex w ROE ROC min
High Quality & Low Capex
High Yield Insider Buys
Historical High Dividend Yields
International Gurus' Top Holdings
James Montier Short Screen
Margin Decliners
Mega Caps
Peter Lynch & Warren Buffett
Peter Lynch Growth w Lower Valuation
Peter Lynch S&L Traded Below Book
PFCF Screener
Piotroski Score Screener
Predictable Growth Companies
Profitable predictable margin expanders
Stocks Sold w less Cash
The Stalwarts
My Screeners
Create My Screener
Value Screens
Stock Ideas
All-In-One Screener
S&P 500 Map
S&P 500 Bubble
S&P 500 Aggregate
Buffett-Munger Screener
Industry Overview
Undervalued Predictable
Benjamin Graham Net-Net
52-week/3Y/5Y Lows
52-week/3Y/5Y Highs
Magic Formula(Greenblatt)
Dividend Stocks
Peter Lynch Screen
S&P500 Grid
Predictable Companies
Spin Off List
Merger and Acquisition List
Historical Low P/B List
Historical Low P/S List
High Short Interest
Upcoming Special Dividends
Delisted Stocks
Model Portfolios
Performances Overview
Most Broadly Held Portfolio
Most Weighted Portfolio
Buffett-Munger Top 25
GF Score <= 100 Top 25
Top 25 Undervalued Predictable
Top 25 52-week Low Predictable
Top 25 Historical Low P/S
Stock Comparison
Airline Stocks
Artificial Intelligence Stocks
Bank Stocks
Biotech Stocks
Blockchain Stocks
Chinese Stocks
Dividend Stocks
EV Stocks
Growth Stocks
Oil Stocks
Value Stocks
Virtual Reality Stocks
Compare More Stocks…
Gurus
Guru Trades
Latest Guru Picks
Real Time Picks
Guru Portfolio
Score Board
Mutual Funds
Top 10 Holdings
Sector Picks
International Picks
Aggregated Portfolio
Consensus Picks
Guru Bargains
Hot Picks
Download Guru Portfolios
Industry Trends
Geographic Trend
ETFs
Options Holdings
European Shorting
Guru Lists
Complete Guru List
Warren Buffett
Bill Gates
Mohnish Pabrai
Carl Icahn
George Soros
David Tepper
Seth Klarman
Bill Ackman
Joel Greenblatt
Charlie Munger
Michael Price
Julian Robertson
Chuck Akre
David Einhorn
Tom Gayner
My Guru Lists
Insiders
Insider Trading Tracker
Real-Time Insider Picks
CEO Buys/Sells
CFO Buys/Sells
Insider Trends
Insider Cluster
Guru + Insider Double Buys
Triple Buys/Sells
Chinese Insider
German Insider
Complete Insider List
Politician Trading Tracker
Real-Time Politician Picks
Complete Politician List
Nancy Pelosi
Mitch Mcconnell
Tommy Tuberville
Josh Gottheimer
Kevin Hern
Thomas R. Carper
Susie Lee
Lois Frankel
Market
US Market Valuation
Buffett Indicator
U.S. Treasury Yield Curve
U.S. Inflation Rate
Presidential Cycle and Stock Market
Shiller P/E
Shiller P/E by Sectors
GF Value for S&P 500 Index
Fed Net Liquidity
Buffett Assets Allocation
Latest IPOs
Global Market Valuation
Global Market Overview
USA
China
Japan
India
Canada
UK
France
Germany
Brazil
Australia
More...
Economic Indicators
Economic Indicators Overview
The Dow Jones Industrial Average (DJIA)
SP 500 Index
Nasdaq Composite Index
Gross Domestic Product (GDP)
Shiller PE
Ratio of Wilshire 5000 over GNP
Civilian Unemployment Rate
Russell 2000 Index
CBOE Volatility Index (VIX)
Total Nonfarm Payrolls: All Employees
More...
Sector & Industry Performance
Global Industry Overview
USA
Asia
Europe
Canada
UK/Ireland
Oceania
Latin America
Africa
India/Pakistan
Articles
Articles
Editors' Picks
Stock Market News
Q&A with Gurus
Guru Stock Picks
Insider Transaction
Earning Reports
CEO Shareholder Letters
Podcast
Earnings Call Transcripts
Software Stock News
Biotechnology Stock News
Hardware Stock News
Banks Stock News
Metals & Mining Stock News
Drug Manufacturers Stock News
All Articles
Submit Articles
Submit Article Online
Contributor Guidelines
Tools
Model Portfolios
All-In-One Screener
Data Batch Download
Guru Portfolio Download
Insider Data Download
Excel Add-In
Google Sheets Add-On
API
Manual of Stocks
DCF Calculator
WACC Calculator
Interactive Chart
Maps
Fund Letters Archive
Stock Comparison Table
Mobile App
Discussion Board
GuruGPT
Financial Calendar
Embed Widgets
Stock Market Holidays
Discussion
Discussion Board
GuruFocus Discord
ETF
Data
Pricing
Tutorials
Tutorials
Financial Glossary
FAQ
Change Log
Contact Us
Support
Chat Support
Create a ticket
Book Demo
User Engagement Meeting
469-248-6885
Status
Take Survey
Ask the community in Discord
Subscribe
Free Trial
Group Subscription
Refer a Friend and Earn One Month of Free Membership
GURUFOCUS.COM
STOCK LIST
Healthcare
Biotechnology
Regulus Therapeutics Inc (NAS:RGLS)
News
Regulus Therapeutics Inc
NAS
:RGLS (USA) Â
$ 2.35
-0.22 (-8.59%)
10:08 PM EST
P/E:
At Loss
P/B:
2.23
Market Cap:
$ 153.84M
Enterprise V:
$ 145.89M
Volume:
286.77K
Avg Vol (2M):
4.78M
Warning! GuruFocus detected 2 Severe warning signs with RGLS.
Try a 7-Day Free Trial
to check it out.
Also Trade In:
Volume:
286.77K
Market Cap $:
153.84M
PE Ratio:
At Loss
Avg Vol (2M):
4.78M
Enterprise Value $:
145.89M
PB Ratio:
2.23
Alerts
Website
SEC Filings
Stock PDF
Dataset
Financial Download
Manual of Stocksâ„¢
Compare
0
Summary
30-Y Financials
Estimates
DCF
Dividend
Guru Trades
Insider
Interactive Chart
Filings
Transcripts
News
Compare
Stock PDF
Ownership
Operating
Checklist
Vote
Definitions
Regulus Therapeutics Inc (NAS:RGLS) Stock News, Headlines & Updates
Regulus Therapeutics Inc Stock News from GuruFocus
Total 96
1
2
3
Mar 23, 2024
Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements
GuruFocus Research
•
3:33am
Mar 21, 2024
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
PRNewswire
•
4:00pm
Mar 12, 2024
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
PRNewswire
•
6:00am
Feb 08, 2024
Regulus Therapeutics Inc To Host Special Update Call Transcript
GuruFocus Research
•
3:46pm
Regulus Therapeutics Inc To Host Investor Event (Virtual) Transcript
GuruFocus Research
•
3:46pm
Regulus Therapeutics Inc at Canaccord Genuity Growth Conference Transcript
GuruFocus Research
•
3:46pm
Q3 2022 Regulus Therapeutics Inc Earnings Call Transcript
GuruFocus Research
•
3:46pm
Q2 2022 Regulus Therapeutics Inc Earnings Call Transcript
GuruFocus Research
•
3:46pm
Q1 2022 Regulus Therapeutics Inc Earnings Call Transcript
GuruFocus Research
•
3:46pm
Q4 2021 Regulus Therapeutics Inc Earnings Call Transcript
GuruFocus Research
•
3:46pm
Q3 2021 Regulus Therapeutics Inc Earnings Call Transcript
GuruFocus Research
•
3:46pm
Regulus Therapeutics Inc Announces Strategic Prioritization of RGLS8429 Call Transcript
GuruFocus Research
•
3:46pm
Q2 2021 Regulus Therapeutics Inc Earnings Call Transcript
GuruFocus Research
•
3:46pm
Regulus Therapeutics Inc at Oppenheimer Rare & Orphan Disease Summit (Virtual) Transcript
GuruFocus Research
•
3:46pm
Q1 2021 Regulus Therapeutics Inc Earnings Call Transcript
GuruFocus Research
•
3:46pm
Regulus Therapeutics Inc Results from the First Cohort of Patients with ADPKD in its Ongoing Phase 1b Clinical Trial of RGLS4326 Call Transcript
GuruFocus Research
•
3:45pm
Nov 22, 2023
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
PRNewswire
•
8:00am
Nov 14, 2023
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
PRNewswire
•
12:03am
Oct 19, 2023
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PRNewswire
•
8:00am
Sep 20, 2023
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PRNewswire
•
7:00am
Sep 13, 2023
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PRNewswire
•
8:00am
Sep 05, 2023
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
PRNewswire
•
8:00am
Aug 23, 2023
Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023
PRNewswire
•
8:00am
Aug 08, 2023
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
PRNewswire
•
4:00pm
Aug 02, 2023
Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
PRNewswire
•
8:00am
Jul 18, 2023
Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference
PRNewswire
•
8:00am
Jun 27, 2023
Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PRNewswire
•
8:00am
Jun 23, 2023
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
PRNewswire
•
8:00am
Jun 25, 2021
Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021
PRNewswire
•
7:00am
Jun 21, 2021
Regulus Therapeutics to Present Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021
PRNewswire
•
6:01am
May 21, 2021
Regulus Therapeutics Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program
PRNewswire
•
8:01am
May 19, 2021
Regulus Therapeutics Stock Shows Every Sign Of Being Possible Value Trap
GF Value
•
6:12am
May 14, 2021
Regulus Therapeutics to Present at the Oppenheimer Rare & Orphan Disease Summit
PRNewswire
•
4:00pm
May 06, 2021
Regulus Therapeutics Announces Timing for First Quarter 2021 Financial Results Webcast and Conference Call
PRNewswire
•
5:01pm
May 03, 2021
Regulus Therapeutics Announces Top-Line Data from the First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PRNewswire
•
7:02am
Mar 10, 2021
Regulus Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Recent Updates
PRNewswire
•
7:03pm
Mar 06, 2021
Regulus Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
PRNewswire
•
7:01pm
Feb 10, 2021
Regulus Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PRNewswire
•
11:04am
Jan 27, 2021
Regulus Announces Addition to Board of Directors
PRNewswire
•
11:04am
Jan 05, 2021
Regulus Therapeutics to Present at the H.C. Wainwright Virtual BioConnect Conference
PRNewswire
•
11:04am
Total 96
1
2
3
Show
20
40
60
80
100
No data
Entries
Headlines
Total 0
1
No recent news